 | | Vol. 13.31 – 19 August, 2021 |
| |
|
|
| Researchers identified mechanisms of TNBC resistance to Sacituzumab Govitecan through RNA and whole-exome sequencing of pre-treatment and post-progression specimens.
[Cancer Discovery] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Lysine acetyltransferase 6A (KAT6A)-acetylated H3K23-mediated recruitment of tripartite motif-containing 24–SMAD3 complex to chromatin increased SMAD3 activation and immune response-related cytokine expression, leading to enhanced breast cancer stem-like cell stemness, myeloid-derived suppressor cell recruitment, and TNBC metastasis.
[Advanced Science] |
|
|
|
| Scientists reported that seryl tRNA synthetase, a key enzyme for protein biosynthesis, could translocate into the nucleus in a glucose-dependent manner to suppress key genes involved in the de novo lipid biosynthesis.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators reported that activation of β-catenin, an oncogene of the WNT signaling pathway, inhibited proliferation of BRCA1/2-deficient cells.
[Nature Communications] |
|
|
|
| Neuregulin-1 (NRG1) was expressed in HER2-positive breast cancer-derived fibroblasts at significantly higher levels than in cancer cells. NRG1 and the conditioned media from cancer-associated fibroblasts phosphorylated HER3 and AKT in cancer cells and mediated trastuzumab resistance.
[Clinical Cancer Research] |
|
|
|
| Slit2 increased recruitment of M1-like tumor-associated macrophages (M1-TAMs) to the tumor and enhanced the ability of M1-TAMs to phagocytose tumor cells in vitro and in vivo.
[Cancer Research] |
|
|
|
| Researchers identified decaprenyl diphosphate synthase subunit 1 (PDSS1) as an essential gene for TNBC metastasis. PDSS1 expression was significantly upregulated in TNBC tissues compared to adjacent normal tissues and was positively associated with poor survival among TNBC patients.
[Cancer Research] |
|
|
|
| Transcriptome analyses indicated that chronic estrogen receptor alpha (ERα) inhibition triggered a broad immunosuppressive program in ER-positive breast cancer cells, which was subsequent to their growth arrest and involved the activation of multiple immune checkpoints together with the silencing of the antigen presentation machinery.
[Molecular Oncology] |
|
|
|
| Exogenous leptin abrogated tamoxifen-mediated growth inhibition and potentiated breast tumor growth even in the presence of tamoxifen.
[npj Breast Cancer] |
|
|
|
| Peroxiredoxin 1 (PRDX1) inactivation in mammary fibroblasts occured via SRC-induced phosphorylation of PRDX1 TYR194 and not through the expected direct oxidation of CYS52 in PRDX1 by ROS.
[British Journal of Cancer] |
|
|
|
| To assess a potential combination strategy in a CDK4/6i resistant breast cancer population, the authors investigated the mechanism of action of ZEN-3694 combined with CDK4/6 inhibitors in the ER+ cell lines resistant to palbociclib or abemaciclib.
[Cancer Gene Therapy] |
|
|
|
| Predicted pathogenic mutation R532Q within S5 disrupted the S5/S6 interaction leading to gain-of-function of the channel, which promoted breast cancer cell progression through strengthening of the TRPV6/PI3K interaction, activation of a PI3K/Akt/GSK-3β cascade, and up-regulation of epithelial-mesenchymal transition and anti-apoptosis.
[Communications Biology] |
|
|
|
| Circular RNA circ-ERBB2 knockdown constrained TNBC growth in vivo and reduced Warburg effect, accelerated apoptosis, repressed proliferation, migration, and invasion of TNBC cells in vitro.
[Molecular and Cellular Biology] |
|
|
|
|
| Investigators summarize the principal molecular, clinical, and safety characteristics of approved and experimental anti-HER2 antibody-drug conjugates, contextualizing the current and future landscape of drug development.
[Breast Cancer Research] |
|
|
|
| The authors present a comprehensive overview of the current literature concerning how miRNAs and cyclooxygenase-2 signaling interact in breast cancer progression.
[Clinica Chimica Acta] |
|
|
|
|
| Seagen, Inc. and RemeGen Co., Ltd. announced that the two companies have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody-drug conjugate.
[Seagen, Inc.] |
|
|
|
| Carrick Therapeutics announced that the US FDA has granted Fast Track designations to samuraciclib in combination with fulvestrant for CDK4/6i resistant HR+, HER2– advanced breast cancer and samuraciclib in combination with chemotherapy for the treatment of locally advanced or metastatic TNBC.
[Carrick Therapeutics] |
|
|
|
|
| October 14, 2021
Wädenswil, Switzerland |
|
|
|
|
|
| | Purdue University – West Lafayette, Indiana, United States |
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | University of Gothenburg – Gothenburg, Sweden |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
